”Come 2013 we will be fit for fight”
The CEO of Exiqon acknowledges that the company has under-performed in the US. A new sales strategy and new, scientific workers are going to turn it all around.
For the second quarter running the Danish medtech company Exiqon has presented a record-turnover powered by increasing sales figures in Europe. However, the sale of research products and services in the US has dropped off by 14 % compared with the same period last year. And that development needs to be turned around.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
CEO: ”It’s pretty well done by Exiqon”
For abonnenter
